Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT01424930 is registered in ClinicalTrials.gov with Janssen-Ortho Inc., Canada as lead sponsor.

NCT NCT01424930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01424930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Subjects With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Janssen-Ortho Inc., Canada
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
May 31, 2013
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate neoplasms